Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biol Pharm Bull ; 44(10): 1380-1390, 2021.
Article in English | MEDLINE | ID: mdl-34602546

ABSTRACT

Claudin-5 is the dominant tight junction protein in brain endothelial cells and exclusively limits the paracellular permeability of molecules larger than 400 Da across the blood-brain barrier (BBB). Its pathological impairment or sustained down-regulation has been shown to lead to the progression of psychiatric and neurological disorders, whereas its expression under physiological conditions prevents the passage of drugs across the BBB. While claudin-5 enhancers could potentially act as vascular stabilizers to treat neurological diseases, claudin-5 inhibitors could function as delivery systems to enhance the brain uptake of hydrophilic small-molecular-weight drugs. Therefore, the effects of claudin-5 manipulation on modulating the BBB in different neurological diseases requires further examination. To manipulate claudin-5 expression levels and function, several claudin-5 modulating molecules have been developed. In this review, we first describe the molecular, cellular and pathological aspects of claudin-5 to highlight the mechanisms of claudin-5 enhancers/inhibitors. We then discuss recently developed claudin-5 enhancers/inhibitors and new methods to discover these molecules.


Subject(s)
Blood-Brain Barrier/drug effects , Capillary Permeability/drug effects , Claudin-5/agonists , Claudin-5/antagonists & inhibitors , Animals , Blood-Brain Barrier/metabolism , Claudin-5/metabolism , Drug Discovery/methods , Endothelial Cells/cytology , Endothelial Cells/drug effects , Humans , Models, Animal , Tight Junctions/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...